Funding round for Nouscom
Cancer immunotherapy development · Switzerlandfunding round withM Ventures, Revelation Partners
advised by
- Sell-side
- Walder Wyss
Nouscom completes an oversubscribed Series D financing round of €120m. The Swiss biotech company, backed by EQT, develops next-generation cancer immunotherapies. The round is led by M Ventures and Revelation Partners, with further investors including Angelini Industries, the European Investment Bank and Neva SGR.
- Lead investor
- M Ventures, Revelation Partners
- Target
- Nouscom
- Type
- Funding round
- Sector
- Healthcare & Medtech
- Country
- Switzerland
- First reported
- 22/10/2026
- Sell-side
- Walder Wyss, according to the source
- Source
- Nouscom
Deal-Radar no. 43-076 · publicly reported, without guarantee · SourcingClub was not involved in this transaction. Report an error · Method
Transactions by M Ventures, Revelation Partners
So far this is the only transaction by M Ventures, Revelation Partners published in the Deal-Radar. New deals are added every Monday.
Venture and growth in Week 43/2026
All deals in October 2026Every Monday, all deals of the previous week, with source.
Information from public sources, without guarantee and without claim to completeness. No investment or legal advice. Published on 26 October 2026.